Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
Strong second quarter of launch for Rubraca®
(rucaparib) in U.S. with $14.6M reported in net sales
Positive topline data from the ARIEL3 study reported on June 19,
2017; presentation of full dataset confirmed at European Society for
Medical Oncology 2017 Congress in Madrid
Clovis plans to submit a supplemental New Drug Application (sNDA)
for a second-line and later maintenance treatment indication before
Pivotal Phase 3 Trials Planned for 2017 will Evaluate Rubraca in Combination with Opdivo, Rubraca as Monotherapy, and Opdivo as Monotherapy in First Line Maintenance Treatment for Advanced Ovarian and Advanced Triple-Negative Breast CancersPhase 2 Trial will Evaluate Opdivo in Combination with Rubraca and Other Compounds in Metastatic Castration-Resistant Prostate Cancer (NEW YORK and BOULDER, CO, July 31, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) and Clovis Oncology, Inc. (Nasda...
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 19, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter
2017 financial results on Wednesday, August 2, 2017, after the close of
the U.S. financial markets. Clovis’ senior management will host a
conference call and live audio webcast at 4:30 p.m. ET that day to
discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.